Nov 18, 2021 Novo Nordisk has entered into an agreement to acquire Dicerna Pharmaceuticals in a $3,300,000,000 deal.

Novo Nordisk based at Bagsværd, Hovedstaden, Denmark.
“Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.”

Acquirer’s Website: http://www.novonordisk.com

Dicerna Pharmaceuticals based at Lexington, Massachusetts, United States. “Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid interference (RNAi) to develop medicines that silence genes that cause disease.”

Acquiree’s Website: http://www.dicerna.com